A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Completed · Phase 3

Conditions studied: Glaucoma, Ocular Hypertension

In brief

This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).

Key facts

Study ID

NCT01830140

Run by

Allergan

People needed

466

Starts

2013-07-01

Expected to finish

2014-05-01

Last updated by the study team

2015-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of glaucoma or ocular hypertension

You may not qualify if…

• Active ocular disease other than glaucoma or ocular hypertension
• Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)

Where it is running

• Study site — Artesia, California, United States
• Study site — El Paso, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.